Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.2% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. (TNDM) specializes in diabetes care products, specifically insulin pumps, within a sector where innovation and reliability play a vital role in patient care.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.2% on Aug 20, 2024 15:00

• The recent launch of the updated iOS t:connect mobile app to address issues from a previous nationwide recall has sparked investor concerns regarding the company's product quality and potential sales impact.
• Comparisons made between Tandem Diabetes Care and other diabetes-related stocks may have exposed vulnerabilities or obstacles the company is currently encountering, thereby resulting in a pessimistic response from traders.
• The competitive environment within the diabetes care industry, along with the escalating global prevalence of diabetes, likely contributed to the market's negative stance on TNDM's stock performance today.

TNDM Price Chart

TNDM News

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2024-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid

https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-release-updated-ios-tconnect-mobile-app

Tandem Diabetes Care, Inc. (TNDM): Should You Add This Diabetes Stock To Your Portfolio Now?

We recently compiled a list of the 7 Best Diabetes Stocks To Buy Now. In this article, we are going to take a look at where Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stands against the other diabetes stocks. According to the WHO, approximately 422 million individuals globally suffer from diabetes, with the majority residing in countries with […]

https://www.insidermonkey.com/blog/tandem-diabetes-care-inc-tndm-should-you-add-this-diabetes-stock-to-your-portfolio-now-1336752/

Trending Today

Nike Inc. ($NKE) Stock Forecast: Up 6.2% Today

GameStop Corp. ($GME) Stock Forecast: Up 7.9% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.9% Today

NRG Energy Inc. ($NRG) Stock Forecast: Up 5.1% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.3% Today

Bittensor ($TAO) Crypto Forecast: Up 10.7% Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 5.2% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.3% Today

FedEx Corporation ($FDX) Stock Forecast: Down 15.5% Today

Tandem Diabetes Care, Inc. Price History

10.06.2024 - TNDM Stock was up 5.0%

• Tandem Diabetes Care Inc. saw a surprising 23% stock rally, indicating a significant increase in investor confidence and interest in the company's products and services.
• The bullish movement could be attributed to positive developments such as strong quarterly earnings, new product launches, or strategic partnerships that have exceeded market expectations.
• Investors seem optimistic about TNDM's potential growth in the diabetes management market, leading to increased buying activity and driving the stock price higher.
• The rally may also be driven by speculation or market sentiment, with traders taking advantage of the momentum and pushing TNDM shares to higher prices.

20.07.2024 - TNDM Stock was down 5.2%

• The recent launch of the updated iOS t:connect mobile app to address issues from a previous nationwide recall has sparked investor concerns regarding the company's product quality and potential sales impact.
• Comparisons made between Tandem Diabetes Care and other diabetes-related stocks may have exposed vulnerabilities or obstacles the company is currently encountering, thereby resulting in a pessimistic response from traders.
• The competitive environment within the diabetes care industry, along with the escalating global prevalence of diabetes, likely contributed to the market's negative stance on TNDM's stock performance today.

10.04.2024 - TNDM Stock was up 6.8%

• Tandem Diabetes Care stock experienced a strong bullish movement, jumping 22%.
• The recall of the t:connect mobile app and the software bug causing injuries to over 200 insulin pump users did not seem to significantly impact the stock price.
• Investors might be focusing more on the company's growth and new product success as reported in the recent earnings call, which could be driving the positive market movement.
• Despite the software issues and concerns raised by the FDA, the market seems to be optimistic about Tandem Diabetes Care's future prospects and potential profitability.

03.04.2024 - TNDM Stock was up 24.5%

• Tandem Diabetes Care (TNDM) saw strong bullish movement today, marked by a significant increase in its stock price.
• This uptrend follows the company's impressive first-quarter 2024 earnings report, surpassing both EPS and revenue estimates.
• The positive market sentiment towards Tandem Diabetes Care might be influenced by the overall strong performance of healthcare companies like AEON Biopharma, Allarity Therapeutics, and ModivCare.
• Investors are evidently responding positively to Tandem Diabetes Care's growth and success in launching new products, as underscored in the earnings call and reports.

03.04.2024 - TNDM Stock was up 25.3%

• Tandem Diabetes Care (TNDM) stock saw a 26% increase following the company's Q1 2024 earnings announcement.
• TNDM surpassed analyst estimates for earnings per share and revenue, demonstrating robust financial performance.
• The 21.25% earnings surprise and 10.76% revenue increase suggest growth possibilities for the company, boosting investor confidence and driving a bullish market trend.
• Investor optimism was likely fueled by the strong earnings report, leading to a notable price surge in TNDM stock.

15.04.2024 - TNDM Stock was up 6.7%

• Tandem Diabetes Care Inc. experienced a significant stock rally of 89% due to the following reasons:
• The FDA issued a Class I recall for the t:connect Mobile App iOS v2.7, which is used with the t:slim X2 insulin pump, due to serious software problems that could lead to life-threatening conditions. This recall highlighted the importance of the company's products in diabetes management.
• The glitch in the iOS app controlling the insulin pumps caused over 200 injuries, emphasizing the critical role of reliable technology in healthcare devices.
• Despite the negative news surrounding the app recall, the stock rallied as investors may have perceived the issue as addressable and temporary, leading to increased confidence in the company's ability to rectify the situation and maintain its market position.

23.03.2024 - TNDM Stock was up 8.8%

• Tandem Diabetes Care Inc. saw a 31% increase in its stock price, attributed to positive news and upgrades.
• Upgraded from a "sell" to a "hold" rating, the positive change likely boosted investor confidence in the company's future outlook.
• The market responded favorably to the upgrades, indicating a growing optimism about Tandem Diabetes Care's performance and potential growth in the diabetes management sector.
• The bullish movement could also be influenced by general market trends and a heightened interest in healthcare companies specializing in innovative solutions for chronic conditions like diabetes.

24.05.2024 - TNDM Stock was down 5.5%

• The bearish movement in TNDM stock could be attributed to the appointment of a new COO. While leadership changes can bring fresh perspectives, they can also create uncertainty among investors, leading to a sell-off.
• The overall sentiment in the diabetes sector seems positive, with expectations of significant growth in the market for diabetes treatments. However, the recent pullback in diabetes stocks might have influenced TNDM's downward trend.
• Investors may be cautious due to the recent fluctuations in the sector and could be waiting for more clarity on how the new COO's appointment will impact Tandem Diabetes Care's operations and strategy.

26.06.2024 - TNDM Stock was down 8.7%

• TNDM saw a notable decline, likely influenced by DexCom's unfavorable revenue performance and less optimistic guidance.
• The downbeat updates from DexCom may have shaken investor belief in the diabetes care field, triggering a wave of selling in companies like TNDM.
• Investors could be feeling uncertain about the diabetes care industry's prospects, prompting a reassessment of their investments in TNDM and comparable firms.

06.07.2024 - TNDM Stock was up 7.7%

• Tandem Diabetes Care Inc. (TNDM) witnessed a notable surge in its stock price today, attributed to the positive second-quarter financial results.
• The company exceeded analyst expectations, with earnings per share recorded at -48 cents and revenue reaching $221.91 million.
• The favorable financial performance showcased in the recent report likely fueled the increase in the company's stock value, underscoring its competencies in the competitive healthcare sector.
• Given the rising demand for telemedicine solutions and Tandem Diabetes Care Inc.'s emphasis on diabetes management offerings, the company appears to be strongly positioned for future expansion and achievements.

13.07.2024 - TNDM Stock was up 5.7%

• Tandem Diabetes Care (TNDM) saw a significant uptrend likely linked to recent updates about the March 2024 nationwide recall of its t:connect mobile app for iOS devices.
• The company's communication addressing the issue of fast depletion of the insulin pump battery and the planned release of a new app version for enhanced safety likely boosted confidence among investors and consumers.
• Tandem Diabetes Care's proactive handling of the recall and emphasis on user safety may have influenced the favorable market reaction, demonstrating its dedication to quality and customer satisfaction.

02.07.2024 - TNDM Stock was up 16.1%

• Tandem Diabetes Care's stock surged by 16% subsequent to the announcement of their second-quarter earnings, which surpassed projections.
• The company outperformed analyst forecasts for both earnings per share and revenue, indicating robust financial performance and potentially fostering investor confidence.
• The increase in Tandem Diabetes Care's price target and favorable rating following their Q2 results further bolstered the optimistic sentiment surrounding the stock.
• The favorable market outlook for Tandem Diabetes Care might be attributed to the company's ability to surpass expectations and display growth prospects in the diabetes management sector.